Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
The widespread adoption of selective serotonin inhibitors (SSRIs) as first line pharmacological treatments in the management of clinical depression, transformed the landscape of drug therapy for this condition. SSRIs are safer and better tolerated than the tricyclic antidepressants (TCAs) which they replaced. However, they have limitations which may have placed a ceiling on expectations of first-line pharmacological treatment. Notable problems with SSRIs include induction of anxiety on treatment initiation, delayed onset of significant therapeutic effect, sexual dysfunction, sleep disturbance and overall modest efficacy. This talk will describe the development of SSRIs from TCAs and the pharmacological properties that might account for the superior efficacy of TCAs in some people with depression.
zoom.us/j/95199401096?pwd=ancrZ0U1b0RNVmlKL0tQdTQ5SzhLUT09
Meeting ID: 951 9940 1096
Passcode: 937384
